NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
Clinical Trials
30 trialsNCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT04205838 2026-02-27
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT04954820 2026-02-05
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT07274384 2025-12-10
HYPERBOLIC
Università Vita-Salute San Raffaele
Phase 2 Not yet recruiting
NCT04974671 2025-12-04
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Yale University
Phase 2 Recruiting
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03990571 2024-10-18
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT06472388 2024-06-25
EVENET
AC Camargo Cancer Center
Phase 2 Recruiting
NCT03374332 2024-02-08
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Brown University
Phase 2 Active not recruiting
NCT04149821 2023-06-15
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03727841 2022-07-27
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04033432 2022-04-27
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Northwestern University
Phase 2 Unknown
NCT04905056 2021-05-27
A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT02715297 2020-03-10
GlioCave/NOA17
Technical University of Munich
Phase 2 Unknown
NCT02538432 2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT03469804 2019-10-21
KAPKEY
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT01737450 2019-06-24
PIK-ORL
Centre Leon Berard
Phase 2 Completed
NCT03804866 2019-01-15
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
AGC Biologics S.p.A.
Phase 2 Completed
NCT03601624 2018-11-14
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Phase 2 Unknown
NCT01358071 2018-09-27
NGR018
AGC Biologics S.p.A.
Phase 2 Completed
NCT01110668 2017-02-28
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00995007 2016-03-29
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00108069 2015-11-05
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01778530 2015-10-07
TRC105 for Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00908232 2015-01-15
SEQUENTIAL
Janssen-Cilag International NV
Phase 2 Completed
NCT00393094 2012-07-13
Bevacizumab and Irinotecan to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00530140 2011-10-06
FLIDVAX2006
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown
NCT00517621 2011-02-25
Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT00172367 2008-09-26
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
National Taiwan University Hospital
Phase 2 Withdrawn